Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic

References

• Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–6. PMID: 32991794. doi:10.1056/NEJMoa2028436.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920–31. PMID: 32663912. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. PMID: 33301246. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW Jr, Falsey AR, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50. PMID: 34551225. doi:10.1056/NEJMoa2113017.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. PMID: 33378609. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774–85. PMID: 34551225. doi:10.1056/NEJMoa2113017.
   PubMed Web of Science ®Google Scholar
• Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:714170. PMID: 34707602. doi:10.3389/fimmu.2021.714170.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Ruppet RE, et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022;386(11):1046–57. PMID: 35081293. doi:10.1056/NEJMoa2116414.
   PubMed Web of Science ®Google Scholar
• Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y, Carfi A, Edwards DK, Oestreicher J, Legault H, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Med. 2022;28(5):1042–49. PMID: 35241844. doi:10.1038/s41591-022-01739-w.
   PubMed Web of Science ®Google Scholar
• Poh XY, Tan CW, Lee IR, Chavatte J, Fong S, Prince T, Hartley C, Yeoh AY, Rao S, Chia PY, et al. Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study: a randomized clinical trial. Clin Infect Dis. 2022;ciac345. PMID: 35543372. doi:10.1093/cid/ciac345.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell A, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–46. PMID: 35249272. doi:10.1056/NEJMoa2119451.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Houet PC, et al. Effectiveness of mRNA Covid-19 vaccine among U.S. Health Care Personnel. N Engl J Med. 2021;385(25):e90. PMID: 34551224. doi:10.1056/NEJMoa2106599.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, Al Khatib HA, Coyle P, Ayoub HH, Al Kanaani Z, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83. PMID: 34614327. doi:10.1056/NEJMoa2114114.
   PubMed Web of Science ®Google Scholar
• Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Mukdad Sawsan A, Coyle P, Ayoub HH, Al Kanaani Z, et al. Bnt162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature Med. 2021;27(12):2136–43. PMID: 34728831. doi:10.1038/s41591-021-01583-4.
   PubMed Web of Science ®Google Scholar
• Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, Pannaraj PS, Irby K, Bline KE, Maddux AB, et al. Bnt162b2 protection against the Omicron variant in children and adolescents. N Engl J Med. 2022;386(20):1899–909. PMID: 35353976. doi:10.1056/NEJMoa2202826.
   PubMed Web of Science ®Google Scholar
• Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327(7):639–51. PMID: 35060999. doi:10.1001/jama.2022.0470.
   PubMed Web of Science ®Google Scholar
• Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, Gallagher E, Thelwall S, Groves N, Dabrera G, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386(4):340–50. PMID: 35021002. doi:10.1056/NEJMoa2115481.
   PubMed Web of Science ®Google Scholar
• Hara M, Furue T, Fukuoka M, Iwanaga K, Matsuishi E, Miike T, Sakamoto Y, Mukai N, Kinugasa Y, Shigyo M, et al. Real-World effectiveness of the mRNA COVID-19 vaccines in Japan: a case–control study. Vaccines. 2022;10(5):779. PMID: 35632535. doi:10.3390/vaccines10050779.
   Web of Science ®Google Scholar
• Japanese Ministry of Health, Labor and welfare. Shingata CORONA VIRUS Kansensyou COVID-19 Shinryo no Tebiki Dai 7.2 Han [Our environment: the practice guideline for novel Corona virus infection COVID-19 ver 7.2]. Tokyo (Japan) Affairs; 2022 May 9 [ accessed 2022 May 10]. https://www.mhlw.go.jp/content/000967699.pdf
   Google Scholar
• Yamamoto K, Ohmagari N. Microbiological testing for coronavirus disease 2019. JMA J. 2021;4:67–75. PMID: 33997438. doi:10.31662/jmaj.2021-0012.
   PubMedGoogle Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–58. PMID: 23208313. doi:10.1038/bmt.2012.244.
   PubMed Web of Science ®Google Scholar
• Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, Arioka H, Yanai H, Huramochi JKY, Genei Ihara G, et al. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study). Clin Infect Dis. 2022;ciac635. doi:10.1093/cid/ciac635.
   PubMed Web of Science ®Google Scholar
• The National Institute of Infectious Diseases. Omicron Kabu Ryukouki ni okeru Shingata CORONA Vaccine no Yukosei [Our environment: Vaccine effectiveness of novel Corona vaccine during Omicron surge-Interim report] Tokyo (Japan) [ accessed 2022 Feb 2]. https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10966-covid19-71.html.
   Google Scholar